Complement in different stages of HIV infection and pathogenesis

被引:13
作者
Speth, C
Stoiber, H
Dierich, MP
机构
[1] Univ Innsbruck, Inst Hyg & Social Med, A-6020 Innsbruck, Austria
[2] Ludwig Boltzmann Inst AIDS Res, Innsbruck, Austria
关键词
HIV; complement; co-infection; therapy;
D O I
10.1159/000070211
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
The complement system is one of the most important weapons of innate immunity and is involved in all infectious processes. It is not only a mechanism for direct protection against an invading pathogen but it also interacts with the adaptive immunity to optimize the pathogenspecific humoral and cellular defence cascade in the body. One of the greatest challenges for the complement system is infection by HIV with its chronic course and sequential destruction of immune cells and immune organs. Due to its dual role as direct effector and as fine tuner of adaptive immunity, we focussed on complement in this review and analysed in detail the contribution of complement to the antiviral defence and to HIV pathogenesis on the one hand and the complement evasion strategies of the virus on the other hand. In the present review, this interplay between complement and the virus is illuminated for the three different stages of HIV pathogenesis and for events during therapy: (1) the acute infection process with the early events in mucosa and serum; (2) the asymptomatic stage with the complex interplay between complement-induced lysis and viral evasion strategies; (3) the symptomatic infection and AIDS stage with progressive destruction of the lymph nodes, opportunistic infections and development of neuropathogenesis, and (4) finally, during highly active antiretroviral therapy and in vaccination approaches. Copyright (C) 2003 S. Karger AG, Basel.
引用
收藏
页码:247 / 257
页数:11
相关论文
共 108 条
[51]   A rational basis for mucosal vaccination against HIV infection [J].
Lehner, T ;
Bergmeier, L ;
Wang, YF ;
Tao, L ;
Mitchell, E .
IMMUNOLOGICAL REVIEWS, 1999, 170 :183-196
[52]   Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques [J].
Lehner, T ;
Wang, YF ;
Cranage, M ;
Bergmeier, LA ;
Mitchell, E ;
Tao, L ;
Hall, G ;
Dennis, M ;
Cook, N ;
Brookes, R ;
Klavinskis, L ;
Doyle, C ;
Ward, R .
NATURE MEDICINE, 1996, 2 (07) :767-775
[53]   Simian immunodeficiency virus DNA vaccine trial in macaques [J].
Lu, S ;
Arthos, J ;
Montefiori, DC ;
Yasutomi, Y ;
Manson, K ;
Mustafa, F ;
Johnson, E ;
Santoro, JC ;
Wissink, J ;
Mullins, JI ;
Haynes, JR ;
Letvin, NL ;
Wyand, M ;
Robinson, HL .
JOURNAL OF VIROLOGY, 1996, 70 (06) :3978-3991
[54]   DECAY-ACCELERATING FACTOR (CD55) PROTECTS HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 FROM INACTIVATION BY HUMAN-COMPLEMENT [J].
MARSCHANG, P ;
SODROSKI, J ;
WURZNER, R ;
DIERICH, MP .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (01) :285-290
[55]   INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA CAN BE INDUCED FROM MONONUCLEAR PHAGOCYTES BY HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 BINDING TO THE CD4 RECEPTOR [J].
MERRILL, JE ;
KOYANAGI, Y ;
CHEN, ISY .
JOURNAL OF VIROLOGY, 1989, 63 (10) :4404-4408
[56]   B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells [J].
Moir, S ;
Malaspina, A ;
Li, YX ;
Chun, TW ;
Lowe, T ;
Adelsberger, J ;
Baseler, M ;
Ehler, LA ;
Liu, SY ;
Davey, RT ;
Mican, JAM ;
Fauci, AS .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (05) :637-645
[57]   Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors [J].
Montefiori, DC ;
Pantaleo, G ;
Fink, LM ;
Zhou, JT ;
Zhou, JY ;
Bilska, M ;
Miralles, GD ;
Fauci, AS .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (01) :60-67
[58]   BINDING OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TO THE C3B/C4B RECEPTOR CR-1 (CD35) AND RED-BLOOD-CELLS IN THE PRESENCE OF ENVELOPE-SPECIFIC ANTIBODIES AND COMPLEMENT [J].
MONTEFIORI, DC ;
GRAHAM, BS ;
ZHOU, JY ;
ZHOU, JT ;
AHEARN, JM .
JOURNAL OF INFECTIOUS DISEASES, 1994, 170 (02) :429-432
[59]   COMPLEMENT CONTROL PROTEINS, CD46, CD55, AND CD59, AS COMMON SURFACE CONSTITUENTS OF HUMAN AND SIMIAN IMMUNODEFICIENCY VIRUSES AND POSSIBLE TARGETS FOR VACCINE PROTECTION [J].
MONTEFIORI, DC ;
CORNELL, RJ ;
ZHOU, JY ;
ZHOU, JT ;
HIRSCH, VM ;
JOHNSON, PR .
VIROLOGY, 1994, 205 (01) :82-92
[60]  
Osaka H, 1999, J CELL BIOCHEM, V73, P303, DOI 10.1002/(SICI)1097-4644(19990601)73:3<303::AID-JCB2>3.3.CO